交银国际发布研报称，维持荣昌生物(09995)136港元目标价，维持买入评级。剔除BD和公允价值收益 对利润的贡献，预计4Q25公司主营业务已实现或接近盈亏平衡，早于该行此前的预期。随着泰它西普 和RC148出海后、更多研发费用由海外合作伙伴承担，该行看好2026年主业利润率进一步改善的空间。 随着关键产品相继BD出海，2026年该行看好 1)泰它西普和维迪西妥在海外注册研究上的进展，包括泰它西普MGIII期入组(预计1H26完成入组、 1H27读出)和SSIII期启动(1H26)、维迪西妥实现首个海外BLA申报(1H26，2LUC)和1LUCIII期数据的读 出；2)中国内地泰它西普MG适应症纳入医保后的销售放量，以及SS、IgAN等更多大适应症的获批；3) 早期品种(包括RC148、RC118、新型ADCRC278等)在更多适应症上的推进，相关数据读出有望持续催 化股价。 2026年1月30日，公司发布2025年年度业绩预告，预计全年实现营业收入约32.5亿元(人民币，下同)，同 比增长约89%；预计实现净利润约7.16亿元，扣非净利润约7,850万元，均实现同比扭亏为盈。本次业绩 表现显著超出该行及市场 ...

智通财经APP获悉，交银国际发布研报称，维持荣昌生物(09995)136港元目标价，维持买入评级。剔除 BD和公允价值收益对利润的贡献，预计4Q25公司主营业务已实现或接近盈亏平衡，早于该行此前的预 期。随着泰它西普和RC148出海后、更多研发费用由海外合作伙伴承担，该行看好2026年主业利润率进 一步改善的空间。 交银国际主要观点如下： 核心产品放量叠加BD兑现，驱动2025年扭亏为盈 2026年1月30日，公司发布2025年年度业绩预告，预计全年实现营业收入约32.5亿元（人民币，下 同），同比增长约89%；预计实现净利润约7.16亿元，扣非净利润约7,850万元，均实现同比扭亏为盈。 本次业绩表现显著超出该行及市场此前预期，且盈利拐点出现时点亦较此前判断明显前移。 根据公告，公司业绩高增长的主要由三方面驱动 1）核心产品商业化持续放量：泰它西普和维迪西妥单抗在中国内地市场的销售快速放量，持续贡献业 绩核心增量；2）BD收入确认显著增厚利润端：2025年公司分别与Vor Biopharma就泰它西普海外权益 达成授权、与参天制药就眼科创新药RC-28E注射液达成大中华及亚洲地区授权，获得的首付款及潜在 股 ...

Core Viewpoint - Rongchang Biologics has issued a positive earnings forecast, expecting approximately 3.25 billion yuan in revenue for the previous year, representing a year-on-year growth of about 89%, and a net profit of around 716 million yuan, with a non-GAAP net profit of approximately 78.5 million yuan, indicating a turnaround from losses in the previous year [1] Group 1: Financial Performance - The reported performance significantly exceeds both the bank's and market's previous expectations, with the timing of the profitability inflection point occurring earlier than previously anticipated [1] - The company is expected to see further improvement in its main business profit margins this year, driven by the overseas expansion of Tai Tasi Pu and RC148, as well as a greater share of R&D costs being borne by overseas partners [1] Group 2: Investment Outlook - The bank maintains a "Buy" rating for Rongchang Biologics with a target price of 136 HKD, highlighting optimism for the company's upcoming milestones, including the enrollment of Tai Tasi Pu in MG III and the initiation of SS III, as well as the first overseas BLA submission for Vidi Xi Tuo and data readouts for 1L UC III [1] - Anticipated sales volume increases following the inclusion of Tai Tasi Pu in the mainland's medical insurance for MG indications, along with approvals for major indications such as SS and IgAN, are expected to drive further growth [1] - Progress in early-stage products (RC148, RC118, new ADCRC278, etc.) and the advancement of additional indications are likely to provide continuous catalysts for the stock price [1]

Market Overview - The Hang Seng Index closed at 26,776 points, down 2.2%, while the Hang Seng China Enterprises Index fell 2.5% to 9,080 points[1] - Total turnover in the Hong Kong stock market was HKD 347.9 billion, a 15.4% increase from HKD 301.6 billion last Friday[1] - The materials, energy, and healthcare indices dropped by 6.0%, 4.0%, and 3.5% respectively, while consumer staples, utilities, and financials saw smaller declines of 0.2%, 1.1%, and 1.6%[1] Stock Performance - Sands China (1928 HK) and Lenovo Group (992 HK) led the blue-chip gainers, rising by 4.1% and 1.8% respectively[1] - BYD Company (1211 HK) and China Unicom (762 HK) were the biggest losers, falling by 6.9% and 6.3% respectively[1] Commodity Prices - Oil prices decreased from USD 65 to approximately USD 62, while gold prices fell from USD 5,400 to around USD 4,700[2] - The decline in commodity prices is attributed to reduced geopolitical risks and expectations of limited interest rate cuts by the Federal Reserve[2] Economic Indicators - The ISM Manufacturing PMI for January in the U.S. was reported at 52.6, exceeding December's 47.9 and the market forecast of 48.3[3] - In mainland China, the transaction volume of new homes in 30 major cities reached 1.48 million square meters, a year-on-year increase of 983.8% due to last year's Spring Festival holiday[3] Industry Insights - Macau's gaming revenue for January was AUD 22.63 billion, up 24.0% year-on-year and 8% month-on-month, exceeding market expectations[4] - The healthcare index in Hong Kong fell by 3.5%, with Rongchang Bio (9995 HK) expecting a revenue increase of 89% to RMB 3.25 billion, significantly above market expectations[4] Energy Sector - The energy sector, particularly thermal power and electrical equipment stocks, saw significant declines, with Huaneng International (902 HK) down 6.8%[5] - Recent policy changes by the National Development and Reform Commission regarding electricity pricing have raised concerns in the market, despite potential long-term benefits[5]

Key Insights - The report indicates that the recent market adjustments in A-shares and Hong Kong stocks are primarily technical and emotional, with a positive medium-term outlook for Chinese assets as liquidity and fundamentals remain favorable [2][3] - The report highlights the resilience of the funding environment, despite a significant net outflow of 320 billion yuan from ETFs, suggesting that there is still strong underlying demand for certain asset classes [3] - The manufacturing PMI for January fell to 49.3%, indicating contraction, while the non-manufacturing index also declined to 49.4%, suggesting potential challenges in economic activity [5][6] - The nomination of Kevin Warsh as the next Federal Reserve Chair is expected to influence market sentiment, particularly regarding inflation expectations and interest rates, which may impact risk assets [5][10] - The report discusses the recent performance of high-dividend sectors, noting that they have outperformed the market as risk appetite declines, with recommendations to focus on stable high-dividend stocks [11][12] - The report emphasizes the ongoing interest in IPOs in the Hong Kong market, with a strong performance in recent listings, suggesting continued investor appetite for new equity offerings [12][30] - The introduction of a unified capacity pricing mechanism for independent energy storage is expected to enhance the profitability and stability of the energy sector, particularly for leading companies in the storage and power generation space [27][28] - The report notes the recovery in the second-hand housing market, with increased transaction volumes and stable prices, particularly in first-tier cities, indicating a potential rebound in the real estate sector [24][29] - The report highlights the commercial acceleration of microbial protein production, driven by regulatory approvals and increasing demand for alternative protein sources, suggesting a growing investment opportunity in this sector [25]

Group 1 - The pharmaceutical and biotechnology sector has shown strong capital attraction, with significant market sentiment recovery, as evidenced by the net inflow of 667 million yuan into the Kexin Innovation Drug ETF (589720) over ten consecutive trading days [1] - Recent mergers and acquisitions, such as China National Pharmaceutical's acquisition of Hejia Bio for 1.2 billion yuan and Rongchang Bio's exclusive licensing agreement with AbbVie worth up to 650 million USD, have boosted market confidence and highlighted the internationalization efforts of Chinese pharmaceutical companies [1] - The investment logic in the pharmaceutical sector is supported by "innovation realization" and "valuation repair," with domestic innovative drugs entering a commercialization and internationalization phase, indicating improved cash flow for leading pharmaceutical companies [1] Group 2 - The policy environment is increasingly supportive, with the Ministry of Commerce and other departments issuing guidelines to promote high-quality development in the pharmaceutical retail sector, encouraging mergers and acquisitions, which may lead to increased industry concentration [2] - Comprehensive support for innovative drug development through policy implementation lays a foundation for sustained growth in the industry [2] - The Kexin Innovation Drug ETF (589720) closely tracks the Kexin Innovation Drug Index, focusing on leading companies, with over 90% of its holdings in innovative drug firms, making it an attractive option for interested investors [2]

Market Overview - The A-share market experienced a significant decline, with the Shanghai Composite Index dropping 2.48% to 4015.75 points and the Shenzhen Component Index falling 2.69% to 13824.35 points, as trading volume reached 2.6 trillion yuan, slightly lower than the previous day [1] - The market sentiment was negatively impacted by the nomination of Kevin Warsh as the next Federal Reserve Chairman, raising concerns about prolonged high interest rates and a notable drop in risk appetite [1] Pharmaceutical and Biotech Sector - The pharmaceutical and biotech sector demonstrated strong capital attraction, with the Guotai Innovation Drug ETF (589720) seeing a net inflow of 667 million yuan over ten consecutive trading days [3][4] - Key mergers and acquisitions, such as China Biopharmaceutical's acquisition of Hejia Biotech for 1.2 billion yuan and Rongchang Biopharmaceutical's exclusive licensing agreement with AbbVie worth up to 650 million USD, have boosted market confidence and highlighted the global competitiveness of Chinese pharmaceutical companies [3][4] - The investment logic in the pharmaceutical sector is supported by "innovation realization" and "valuation recovery," as domestic innovative drugs enter a commercialization and internationalization phase [3][4] Solar Energy Sector - The solar energy sector saw a strong performance, with the solar industry index rising over 2% before retreating, driven by Tesla CEO Elon Musk's proposal for a "space solar" project [5][6] - The sector is transitioning from a "post-decline rebound" to a deeper "supply-demand pattern reshaping," with significant potential for Chinese solar companies due to their advantages in equipment and core material supply [5][6] - The solar industry has faced intense price competition, leading to significant losses for major players, but recent policies aimed at reducing competition and clearing out outdated capacity are expected to enhance market concentration and improve the profitability of leading firms [5][6] Electric Grid Sector - The electric grid sector is experiencing robust domestic demand, with transformer factories in regions like Guangdong and Jiangsu operating at full capacity, and significant investments expected from the State Grid Corporation [7][8] - Major electric grid equipment companies reported impressive earnings, with projected revenues of 21.205 billion yuan, a 37.18% increase year-on-year, and net profits of 3.163 billion yuan, up 54.35% from the previous year [7][8] - The global energy transition is driving demand for electric grid construction, particularly in underdeveloped regions, presenting substantial growth opportunities for domestic electric grid companies [7][8] Precious Metals Sector - The precious metals sector, particularly gold, is undergoing significant volatility, with COMEX gold prices dropping below 4500 [9][10] - Concerns over monetary policy tightening following Warsh's nomination have led to market sell-offs, exacerbated by high leverage and profit-taking after previous price surges [9][10] - Despite short-term adjustments, long-term support for gold prices remains due to expectations of Federal Reserve rate cuts and ongoing geopolitical tensions [9][10]

郭晨凯 制图 ◎记者 张问之 2026年以来，上市公司的回购热潮仍在持续。1月以来，多家A股公司"真金白银"实施回购。其中：步 长制药、兴发集团等在1月披露回购计划后便火速实施；华盛锂电、荣昌生物、依依股份等则因近期公 司股票价格持续超出回购价格上限，为保障回购方案顺利实施而大幅上调回购价格。 梳理可见："基于对公司未来发展前景的信心和对公司内在价值的基本判断"成为多家公司实施回购的重 要缘由；公司回购的股份，多计划用于员工持股计划或股权激励。 以家电龙头美的集团为例，公司最新公告显示，截至1月31日，公司已斥资19.98亿元回购A股股份 2694.37万股。回溯至2025年12月底，公司累计回购股份数量为2056.46万股，支付总金额约为15.10亿 元。这意味着，2026年1月，美的集团回购金额约为4.88亿元。 果链龙头歌尔股份2月2日晚披露，其回购股份比例达到1%。公告显示，截至2月2日，歌尔股份累计回 购股份4054.81万股，斥资约11.08亿元。而截至2025年12月底，其回购股份数量为3449.70万股，支付金 额约9.50亿元。 步长制药、珀莱雅、兴发集团等回购动作则颇为迅速。2月2日晚，步 ...

Performance Highlights - New Yi Sheng (300502.SZ) expects net profit between 9.4 billion and 9.9 billion CNY, a year-on-year increase of 231.24% to 248.86% due to rising demand for high-speed optical modules driven by global computing power investments[4] - Han's Chip (688256.SH) anticipates net profit between 1.85 billion and 2.15 billion CNY, turning from a loss of 450 million CNY last year, benefiting from the growing demand for AI computing power[5] - Zhongji Xuchuang (300308.SZ) projects net profit between 9.8 billion and 11.8 billion CNY, a year-on-year growth of 89.50% to 128.17%, driven by strong customer investment in computing infrastructure[6] - Runze Technology (300442.SZ) expects net profit between 5 billion and 5.3 billion CNY, a year-on-year increase of 179.28% to 196.03%, largely due to non-recurring gains from public REITs issuance[10] Underperformance Highlights - Great Wall Motors (601633.SH) forecasts net profit of 9.912 billion CNY, a year-on-year decline of 21.71% due to increased marketing expenses and competitive pressures[36] - GAC Group (601238.SH) expects a net loss between 8 billion and 9 billion CNY, turning from a profit of 824 million CNY last year, impacted by fierce competition and increased asset impairment provisions[39] - Xiexin Integrated (002506.SZ) anticipates a net loss between 890 million and 1.29 billion CNY, shifting from a profit of 68 million CNY last year due to structural supply-demand issues in the photovoltaic industry[41] - Baile Tianheng (688506.SH) projects a net loss of around 1.1 billion CNY, down from a profit of 3.708 billion CNY last year, primarily due to increased R&D expenses[42] Industry Trends - Technology-driven sectors like AI and innovative pharmaceuticals are leading growth, with companies like New Yi Sheng and Han's Chip benefiting from strong demand and technological advancements[69] - Cost control is becoming a critical competitive advantage, particularly in the energy and manufacturing sectors, as seen with companies like Datang Power (601991.SH) benefiting from lower coal prices[70] - Traditional cyclical industries such as real estate and agriculture are facing significant downward pressure, with companies like Vanke (000002.SZ) and Tianbang Foods (002124.SZ) experiencing substantial losses due to market adjustments[72]

Core Viewpoint - The article highlights the performance forecast of various A-share listed companies, indicating a significant divergence in earnings growth across different sectors, driven by technological advancements, cost control, and industry cycles [4][62]. Group 1: Companies with Strong Earnings Growth - **New Yisheng (300502.SZ)**: Expected net profit of 9.4 billion to 9.9 billion, a year-on-year increase of 231.24% to 248.86%, driven by rising demand for high-speed optical modules due to global computing power investments [6]. - **Han's Laser (688256.SH)**: Expected net profit of 1.85 billion to 2.15 billion, turning from a loss of 0.452 billion in the previous year, benefiting from the increasing demand for AI computing power [8]. - **Zhongji Xuchuang (300308.SZ)**: Expected net profit of 9.8 billion to 11.8 billion, a year-on-year increase of 89.50% to 128.17%, supported by strong investment in computing infrastructure [10]. - **Runze Technology (300442.SZ)**: Expected net profit of 5 billion to 5.3 billion, a year-on-year increase of 179.28% to 196.03%, primarily due to non-recurring gains from public REITs issuance [12]. - **CITIC Securities (601995.SH)**: Expected net profit of 8.542 billion to 10.535 billion, a year-on-year increase of 50% to 85%, driven by steady growth in core business segments [15]. Group 2: Companies with Earnings Below Expectations - **Great Wall Motors (601633.SH)**: Expected net profit of 9.912 billion, a year-on-year decrease of 21.71%, impacted by increased marketing expenses and intense competition [34]. - **GAC Group (601238.SH)**: Expected net profit of -8 billion to -9 billion, turning from a profit of 0.824 billion in the previous year, due to fierce competition and adjustments in product structure [36]. - **GCL-Poly Energy (002506.SZ)**: Expected net profit of -0.89 billion to -1.29 billion, turning from a profit of 0.068 billion, affected by structural supply-demand issues in the photovoltaic industry [38]. - **Boli Tianheng (688506.SH)**: Expected net profit of -1.1 billion, turning from a profit of 3.708 billion, due to increased R&D expenses [39]. - **Daiyue City (000031.SZ)**: Expected net profit of -2.7 billion to -2.1 billion, continuing losses from the previous year, influenced by asset impairment provisions [42]. Group 3: Industry Trends - **Technological Breakthroughs**: Industries driven by technology, such as AI and innovative pharmaceuticals, are showing strong growth, with companies like New Yisheng and Rongchang Bio leading the way [62][63]. - **Cost Control**: The energy and manufacturing sectors are experiencing a clear divide, with companies like Datang Power benefiting from lower coal prices and effective cost management [64]. - **Downward Pressure from Industry Cycles**: The real estate, agriculture, and photovoltaic sectors are under significant pressure, with companies like Vanke and Tianbang Food facing substantial earnings declines [65][66].